UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 158

Sortiert nach

Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease

Journal of the American Society of Nephrology, 2017-11, Vol.28 (11), p.3404-3413

2017

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF‐06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects

Clinical pharmacology in drug development, 2018-06, Vol.7 (5), p.484-497

2018

Volltextzugriff (PDF)

Priority Outcomes in Sickle Cell Disease Treatment: Co-Creation and Implementation of a Preference Exercise With Patients and Caregivers to Inform Drug Development

Journal of patient experience, 2023-01, Vol.10, p.23743735231213767-23743735231213767

2023

Volltextzugriff (PDF)

Peak Thrombin and D-Dimer Levels in Subjects with Severe Hemophilia Receiving Acute Treatment for Bleeding Episodes Experienced during Prophylactic Marstacimab Treatment

Blood, 2020-11, Vol.136 (Supplement 1), p.33-34

2020

Volltextzugriff (PDF)

Practical and Statistical Considerations for the Long Term Follow‐Up of Gene Therapy Trial Participants

Clinical pharmacology and therapeutics, 2024-01, Vol.115 (1), p.139-146

2024

Volltextzugriff (PDF)

Evolution of Antidrug Antibody Assays During the Development of Anti-Tissue Factor Pathway Inhibitor Monoclonal Antibody Marstacimab

The AAPS journal, 2023-09, Vol.25 (5), Article 84

2023

Volltextzugriff (PDF)

Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results

British journal of haematology, 2023-01, Vol.200 (2), p.240-248

2023

Volltextzugriff (PDF)

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Blood, 2011-10, Vol.118 (17), p.4567-4576

2011

Volltextzugriff (PDF)

Progress: Responsiveness Validation of an Electronic Patient Reported Outcome (ePRO) in Adults with Sickle Cell Disease (NCT05407805)

Blood, 2022-11, Vol.140 (Supplement 1), p.2564-2565

2022

Volltextzugriff (PDF)

Effects of stathmin inhibition on the mitotic spindle

Journal of cell science, 2001-03, Vol.114 (Pt 5), p.909-916

2001

Volltextzugriff (PDF)

Validation of Patient-Reported Vaso-Occlusive Crisis Day As a Potential Endpoint in Studies of Sickle Cell Disease

Blood, 2020-11, Vol.136 (Supplement 1), p.17-17

2020

Volltextzugriff (PDF)

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

British journal of haematology, 2023-01, Vol.200 (2), p.229-239

2023

Volltextzugriff (PDF)

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study

Blood, 2024-02, Vol.143 (9), p.796

2024

Volltextzugriff (PDF)

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α

Blood, 2022-11, Vol.140 (Supplement 1), p.7776-7777

2022

Volltextzugriff (PDF)

Mechanical Thrombectomy for Acute Ischemic Stroke : Final Results of the Multi MERCI Trial

Stroke (1970), 2008-04, Vol.39 (4), p.1205-1212

2008

Volltextzugriff (PDF)

The quintessence of immunogenicity reporting for biotherapeutics

Nature biotechnology, 2015-04, Vol.33 (4), p.334-336

2015

Volltextzugriff (PDF)

Phase 1b Study to Evaluate Safety, Tolerability, and Maximum Tolerated Dose of PF-05230907 for Intracerebral Hemorrhage

Stroke (1970), 2021-01, Vol.52 (1), p.294-298

2021

Volltextzugriff (PDF)

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Blood, 2019-11, Vol.134 (Supplement_1), p.2060-2060

2019

Volltextzugriff (PDF)

Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a

Blood, 2020-11, Vol.136 (Supplement 1), p.12-12

2020

Volltextzugriff (PDF)

Validation of patient‐reported vaso‐occlusive crisis day as an endpoint in sickle cell disease studies

European journal of haematology, 2022-09, Vol.109 (3), p.226-237

2022

Volltextzugriff (PDF)

Escalating Single Doses of PF-05230907 (Recombinant Factor Xa Variant FXaI16L) Are Safe and Demonstrate Hemostatic Pharmacology in Healthy Volunteers

Blood, 2016-12, Vol.128 (22), p.3781-3781

2016

Volltextzugriff (PDF)

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a

Blood, 2021-11, Vol.138 (Supplement 1), p.564-564

2021

Volltextzugriff (PDF)

Evaluation of biomarkers for monitoring thrombogenic potential of FXaI16L

Blood coagulation & fibrinolysis, 2020-01, Vol.31 (1), p.16

2020

Volltextzugriff (PDF)

A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations

Blood, 2015-12, Vol.126 (23), p.3502-3502

2015

Volltextzugriff (PDF)

Evaluation of Potential Safety Biomarkers for Monitoring Thrombogenic Potential of FXaI16L

Blood, 2014-12, Vol.124 (21), p.4237-4237

2014

Volltextzugriff (PDF)

1 – 25 von 158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(141)
Mit Volltextzugriff
(146)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(158)
Japanisch
(12)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF‐06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects

Priority Outcomes in Sickle Cell Disease Treatment: Co-Creation and Implementation of a Preference Exercise With Patients and Caregivers to Inform Drug Development

Peak Thrombin and D-Dimer Levels in Subjects with Severe Hemophilia Receiving Acute Treatment for Bleeding Episodes Experienced during Prophylactic Marstacimab Treatment

Practical and Statistical Considerations for the Long Term Follow‐Up of Gene Therapy Trial Participants

Evolution of Antidrug Antibody Assays During the Development of Anti-Tissue Factor Pathway Inhibitor Monoclonal Antibody Marstacimab

Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Progress: Responsiveness Validation of an Electronic Patient Reported Outcome (ePRO) in Adults with Sickle Cell Disease (NCT05407805)

Effects of stathmin inhibition on the mitotic spindle

Validation of Patient-Reported Vaso-Occlusive Crisis Day As a Potential Endpoint in Studies of Sickle Cell Disease

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α

Mechanical Thrombectomy for Acute Ischemic Stroke : Final Results of the Multi MERCI Trial

The quintessence of immunogenicity reporting for biotherapeutics

Phase 1b Study to Evaluate Safety, Tolerability, and Maximum Tolerated Dose of PF-05230907 for Intracerebral Hemorrhage

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a

Validation of patient‐reported vaso‐occlusive crisis day as an endpoint in sickle cell disease studies

Escalating Single Doses of PF-05230907 (Recombinant Factor Xa Variant FXaI16L) Are Safe and Demonstrate Hemostatic Pharmacology in Healthy Volunteers

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a

Evaluation of biomarkers for monitoring thrombogenic potential of FXaI16L

A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations

Evaluation of Potential Safety Biomarkers for Monitoring Thrombogenic Potential of FXaI16L

Suchergebnisse filtern